Senator Markwayne Mullin (R-Oklahoma) recently bought shares of McKesson Corporation (NYSE:MCK). In a filing disclosed on February 04th, the Senator disclosed that they had bought between $15,001 and $50,000 in McKesson stock on January 5th.
Senator Markwayne Mullin also recently made the following trade(s):
- Purchased $15,001 – $50,000 in shares of Stride (NYSE:LRN) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of APi Group (NYSE:APG) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Adobe (NASDAQ:ADBE) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Carpenter Technology (NYSE:CRS) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Amkor Technology (NASDAQ:AMKR) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Monolithic Power Systems (NASDAQ:MPWR) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Citigroup (NYSE:C) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of VSE (NASDAQ:VSEC) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of FirstCash (NASDAQ:FCFS) on 1/5/2026.
- Purchased $15,001 – $50,000 in shares of Deere & Company (NYSE:DE) on 12/29/2025.
McKesson Stock Performance
Shares of NYSE:MCK opened at $819.58 on Thursday. The company has a 50-day simple moving average of $825.54 and a 200 day simple moving average of $776.66. The company has a market capitalization of $101.16 billion, a P/E ratio of 25.51, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. McKesson Corporation has a 52-week low of $570.51 and a 52-week high of $895.58.
McKesson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 10.21%.
Institutional Investors Weigh In On McKesson
A number of large investors have recently added to or reduced their stakes in MCK. Private Wealth Partners LLC boosted its stake in McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after purchasing an additional 1,682 shares during the last quarter. AlphaQuest LLC raised its stake in shares of McKesson by 91.2% in the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares during the last quarter. CW Advisors LLC lifted its holdings in shares of McKesson by 282.5% in the second quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after purchasing an additional 8,130 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of McKesson by 11.9% during the third quarter. Voya Investment Management LLC now owns 598,880 shares of the company’s stock valued at $462,126,000 after buying an additional 63,621 shares during the last quarter. Finally, Central Pacific Bank Trust Division grew its holdings in McKesson by 54.4% during the third quarter. Central Pacific Bank Trust Division now owns 3,913 shares of the company’s stock worth $3,023,000 after buying an additional 1,378 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.
More McKesson News
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: Q3 results beat expectations — McKesson reported adjusted EPS above consensus and revenue roughly in line, driven by volume growth across distribution. Read More.
- Positive Sentiment: Raised FY‑2026 profit guidance — management nudged full‑year adjusted EPS to a range of 38.800–39.200, citing strength in oncology and specialty drug distribution. That modest beat versus consensus supports the growth story. Read More.
- Neutral Sentiment: Analyst sentiment remains largely positive — multiple firms maintain buy/overweight ratings and price targets above current levels (median targets near $860+), so market expectations stay elevated. Read More.
- Neutral Sentiment: Revenue outcome mixed vs. Street — total revenue was essentially in line with estimates, limiting the upside surprise. Read More.
- Negative Sentiment: Operating cash flow weakness — the quarter showed a sharp drop in cash from operations versus last year, raising concerns about working‑capital swings and free‑cash‑flow reliability. Read More.
- Negative Sentiment: Balance sheet and returns red flags — investors pointed to a negative reported return on equity and a rise in total liabilities, which can temper valuation multiples despite strong top‑line. Read More.
- Negative Sentiment: Insider selling and strategic exits — recent insider sales and McKesson’s full exit from the European market add near‑term uncertainty and may prompt profit‑taking. Read More. Read More.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Evercore ISI reaffirmed an “outperform” rating and set a $1,000.00 price objective on shares of McKesson in a research report on Thursday, November 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Wells Fargo & Company increased their price target on shares of McKesson from $816.00 to $914.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Barclays started coverage on McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 price objective for the company. Finally, Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $899.36.
View Our Latest Stock Report on MCK
Insider Buying and Selling at McKesson
In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $861.63, for a total transaction of $283,476.27. Following the completion of the sale, the chief accounting officer owned 328 shares of the company’s stock, valued at approximately $282,614.64. The trade was a 50.08% decrease in their position. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by company insiders.
About Senator Mullin
Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.
About McKesson
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Further Reading
- Five stocks we like better than McKesson
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Forget AI, This Will Be the Next Big Tech Breakthrough
- New gold price target
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
